SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '1C7'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 GLU A 130 CYH A 162 LEU A 196 HIS A 203 GLY A 222	1C7 A 401 (-3.2A) None 1C7 A 401 (-4.1A) None None None	0.62A	1uwhA-4i6fA: 23.4	1uwhA-4i6fA: 26.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 GLU A 130 LEU A 196 HIS A 203 GLY A 222 PHE A 212	1C7 A 401 (-3.2A) None None None None 1C7 A 401 (-4.0A)	1.28A	1uwhA-4i6fA: 23.4	1uwhA-4i6fA: 26.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	ALA A 109 LYS A 111 GLU A 130 CYH A 162 LEU A 196 HIS A 203 GLY A 222	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.1A) None None None	0.66A	1uwhB-4i6fA: 23.1	1uwhB-4i6fA: 26.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 GLU A 130 CYH A 162 LEU A 196 HIS A 203 GLY A 222	1C7 A 401 (-3.2A) None 1C7 A 401 (-4.1A) None None None	0.63A	1uwjA-4i6fA: 22.7	1uwjA-4i6fA: 26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 GLU A 130 CYH A 162 LEU A 196 HIS A 203 GLY A 222	1C7 A 401 (-3.2A) None 1C7 A 401 (-4.1A) None None None	0.62A	1uwjB-4i6fA: 4.5	1uwjB-4i6fA: 26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	LEU A 88 ALA A 109 LYS A 111 GLU A 130 VAL A 143 ILE A 157 TYR A 161	1C7 A 401 ( 4.4A) 1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.5A) None 1C7 A 401 (-3.5A)	0.69A	3k54A-4i6fA: 22.3	3k54A-4i6fA: 27.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3W68_D_VIVD301_0 (ALPHA-TOCOPHEROL TRANSFER PROTEIN)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	5 / 12	VAL A 142 ILE A 155 ILE A 157 LEU A 159 VAL A 143	None None None 1C7 A 401 (-4.0A) 1C7 A 401 (-4.5A)	1.05A	3w68D-4i6fA: undetectable	3w68D-4i6fA: 22.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	5 / 12	LEU A 88 ALA A 109 LEU A 159 GLY A 222 ASP A 223	1C7 A 401 ( 4.4A) 1C7 A 401 (-3.2A) 1C7 A 401 (-4.0A) None None	0.56A	3zbfA-4i6fA: 24.4	3zbfA-4i6fA: 25.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QMS_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 11	ALA A 109 LYS A 111 GLU A 130 ILE A 157 TYR A 161 ASP A 223	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None None 1C7 A 401 (-3.5A) None	0.77A	4qmsA-4i6fA: 30.1	4qmsA-4i6fA: 27.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 LYS A 111 ILE A 157 SER A 166 PHE A 212 GLY A 222	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None None 1C7 A 401 (-4.0A) None	0.64A	4rzvA-4i6fA: 22.4	4rzvA-4i6fA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 LYS A 111 SER A 166 PHE A 212 GLY A 222 GLY A 225	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.0A) None None	1.28A	4rzvA-4i6fA: 22.4	4rzvA-4i6fA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 LYS A 111 SER A 166 PHE A 212 GLY A 222 PHE A 224	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.0A) None None	0.94A	4rzvA-4i6fA: 22.4	4rzvA-4i6fA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	ALA A 109 LYS A 111 CYH A 162 SER A 166 PHE A 212 GLY A 222 GLY A 225	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) 1C7 A 401 (-4.1A) None 1C7 A 401 (-4.0A) None None	1.42A	4rzvB-4i6fA: 22.1	4rzvB-4i6fA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	ALA A 109 LYS A 111 CYH A 162 SER A 166 PHE A 212 GLY A 222 PHE A 224	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) 1C7 A 401 (-4.1A) None 1C7 A 401 (-4.0A) None None	1.04A	4rzvB-4i6fA: 22.1	4rzvB-4i6fA: 26.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	ALA A 109 LYS A 111 CYH A 162 PHE A 212 GLY A 222 ASP A 223 PHE A 224	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) 1C7 A 401 (-4.1A) 1C7 A 401 (-4.0A) None None None	0.78A	4xv2A-4i6fA: 22.7	4xv2A-4i6fA: 28.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	ALA A 109 LYS A 111 CYH A 162 PHE A 212 GLY A 222 ASP A 223 PHE A 224	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) 1C7 A 401 (-4.1A) 1C7 A 401 (-4.0A) None None None	0.72A	4xv2B-4i6fA: 23.0	4xv2B-4i6fA: 28.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 LYS A 111 CYH A 162 PHE A 212 GLY A 222 PHE A 224	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) 1C7 A 401 (-4.1A) 1C7 A 401 (-4.0A) None None	0.78A	5cswA-4i6fA: 22.6	5cswA-4i6fA: 27.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	ALA A 109 LYS A 111 CYH A 162 PHE A 212 GLY A 222 PHE A 224	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) 1C7 A 401 (-4.1A) 1C7 A 401 (-4.0A) None None	0.79A	5cswB-4i6fA: 22.6	5cswB-4i6fA: 27.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_A_032A401_2 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	4 / 6	LYS A 111 PHE A 145 SER A 166 ASP A 223	1C7 A 401 ( 4.7A) None None None	0.83A	5hesA-4i6fA: 6.8	5hesA-4i6fA: 25.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	ALA A 109 LYS A 111 GLU A 130 CYH A 162 LEU A 196 HIS A 203 GLY A 222	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.1A) None None None	0.70A	5hi2A-4i6fA: 22.7	5hi2A-4i6fA: 27.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	5 / 12	ALA A 109 LYS A 111 ILE A 157 PHE A 212 GLY A 222	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.0A) None	0.63A	5hieA-4i6fA: 21.7	5hieA-4i6fA: 27.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	5 / 12	ALA A 109 LYS A 111 ILE A 157 PHE A 212 GLY A 222	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.0A) None	0.65A	5hieB-4i6fA: 21.7	5hieB-4i6fA: 27.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	5 / 12	ALA A 109 LYS A 111 ILE A 157 PHE A 212 GLY A 222	1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.0A) None	0.63A	5hieD-4i6fA: 21.8	5hieD-4i6fA: 27.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	4 / 8	ALA A 109 GLU A 130 CYH A 162 ASP A 223	1C7 A 401 (-3.2A) None 1C7 A 401 (-4.1A) None	0.52A	5owrA-4i6fA: 23.4	5owrA-4i6fA: 30.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VC3_A_DB8A601_1 (WEE1-LIKE PROTEIN KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	7 / 12	GLY A 89 ALA A 109 GLU A 130 TYR A 161 CYH A 162 PHE A 212 ASP A 223	1C7 A 401 ( 4.8A) 1C7 A 401 (-3.2A) None 1C7 A 401 (-3.5A) 1C7 A 401 (-4.1A) 1C7 A 401 (-4.0A) None	0.81A	5vc3A-4i6fA: 25.2	5vc3A-4i6fA: 24.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	LEU A 88 ALA A 109 GLU A 130 VAL A 143 PHE A 212 GLY A 222	1C7 A 401 ( 4.4A) 1C7 A 401 (-3.2A) None 1C7 A 401 (-4.5A) 1C7 A 401 (-4.0A) None	0.69A	5vcvA-4i6fA: 24.8	5vcvA-4i6fA: 25.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCV_A_1N1A404_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	4i6f	SERINE/THREONINE-PRO TEIN KINASE PLK2 (Homo sapiens)	6 / 12	LEU A 88 ALA A 109 LYS A 111 GLU A 130 VAL A 143 GLY A 222	1C7 A 401 ( 4.4A) 1C7 A 401 (-3.2A) 1C7 A 401 ( 4.7A) None 1C7 A 401 (-4.5A) None	0.85A	5vcvA-4i6fA: 24.8	5vcvA-4i6fA: 25.84

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;GLU A 130;CYH A 162;LEU A 196;HIS A 203;GLY A 222","1C7 A 401 (-3.2A);None;1C7 A 401 (-4.1A);None;None;None","0.62A","1uwhA-4i6fA:23.4",null],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;GLU A 130;LEU A 196;HIS A 203;GLY A 222;PHE A 212","1C7 A 401 (-3.2A);None;None;None;None;1C7 A 401 (-4.0A)","1.28A","1uwhA-4i6fA:23.4","1uwhA-4i6fA:26.09"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"ALA A 109;LYS A 111;GLU A 130;CYH A 162;LEU A 196;HIS A 203;GLY A 222","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.1A);None;None;None","0.66A","1uwhB-4i6fA:23.1","1uwhA-4i6fA:26.09"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;GLU A 130;CYH A 162;LEU A 196;HIS A 203;GLY A 222","1C7 A 401 (-3.2A);None;1C7 A 401 (-4.1A);None;None;None","0.63A","1uwjA-4i6fA:22.7","1uwhB-4i6fA:26.09"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;GLU A 130;CYH A 162;LEU A 196;HIS A 203;GLY A 222","1C7 A 401 (-3.2A);None;1C7 A 401 (-4.1A);None;None;None","0.62A","1uwjB-4i6fA:4.5","1uwjA-4i6fA:26.61"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"LEU A  88;ALA A 109;LYS A 111;GLU A 130;VAL A 143;ILE A 157;TYR A 161","1C7 A 401 ( 4.4A);1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.5A);None;1C7 A 401 (-3.5A)","0.69A","3k54A-4i6fA:22.3","1uwjB-4i6fA:26.61"],["3W68_D_VIVD301_0","ALPHA-TOCOPHEROL TRANSFER PROTEIN","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",5,"VAL A 142;ILE A 155;ILE A 157;LEU A 159;VAL A 143","None;None;None;1C7 A 401 (-4.0A);1C7 A 401 (-4.5A)","1.05A","3w68D-4i6fA:undetectable","3k54A-4i6fA:27.36"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",5,"LEU A  88;ALA A 109;LEU A 159;GLY A 222;ASP A 223","1C7 A 401 ( 4.4A);1C7 A 401 (-3.2A);1C7 A 401 (-4.0A);None;None","0.56A","3zbfA-4i6fA:24.4","3w68D-4i6fA:22.96"],["4QMS_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;LYS A 111;GLU A 130;ILE A 157;TYR A 161;ASP A 223","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;None;1C7 A 401 (-3.5A);None","0.77A","4qmsA-4i6fA:30.1","3zbfA-4i6fA:25.96"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;LYS A 111;ILE A 157;SER A 166;PHE A 212;GLY A 222","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;None;1C7 A 401 (-4.0A);None","0.64A","4rzvA-4i6fA:22.4","4qmsA-4i6fA:27.99"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;LYS A 111;SER A 166;PHE A 212;GLY A 222;GLY A 225","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.0A);None;None","1.28A","4rzvA-4i6fA:22.4","4rzvA-4i6fA:26.88"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;LYS A 111;SER A 166;PHE A 212;GLY A 222;PHE A 224","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.0A);None;None","0.94A","4rzvA-4i6fA:22.4","4rzvA-4i6fA:26.88"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"ALA A 109;LYS A 111;CYH A 162;SER A 166;PHE A 212;GLY A 222;GLY A 225","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);1C7 A 401 (-4.1A);None;1C7 A 401 (-4.0A);None;None","1.42A","4rzvB-4i6fA:22.1","4rzvA-4i6fA:26.88"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"ALA A 109;LYS A 111;CYH A 162;SER A 166;PHE A 212;GLY A 222;PHE A 224","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);1C7 A 401 (-4.1A);None;1C7 A 401 (-4.0A);None;None","1.04A","4rzvB-4i6fA:22.1","4rzvB-4i6fA:26.88"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"ALA A 109;LYS A 111;CYH A 162;PHE A 212;GLY A 222;ASP A 223;PHE A 224","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);1C7 A 401 (-4.1A);1C7 A 401 (-4.0A);None;None;None","0.78A","4xv2A-4i6fA:22.7","4rzvB-4i6fA:26.88"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"ALA A 109;LYS A 111;CYH A 162;PHE A 212;GLY A 222;ASP A 223;PHE A 224","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);1C7 A 401 (-4.1A);1C7 A 401 (-4.0A);None;None;None","0.72A","4xv2B-4i6fA:23.0","4xv2A-4i6fA:28.13"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;LYS A 111;CYH A 162;PHE A 212;GLY A 222;PHE A 224","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);1C7 A 401 (-4.1A);1C7 A 401 (-4.0A);None;None","0.78A","5cswA-4i6fA:22.6","4xv2B-4i6fA:28.13"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"ALA A 109;LYS A 111;CYH A 162;PHE A 212;GLY A 222;PHE A 224","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);1C7 A 401 (-4.1A);1C7 A 401 (-4.0A);None;None","0.79A","5cswB-4i6fA:22.6","5cswA-4i6fA:27.56"],["5HES_A_032A401_2","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",4,"LYS A 111;PHE A 145;SER A 166;ASP A 223","1C7 A 401 ( 4.7A);None;None;None","0.83A","5hesA-4i6fA:6.8","5cswB-4i6fA:27.56"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"ALA A 109;LYS A 111;GLU A 130;CYH A 162;LEU A 196;HIS A 203;GLY A 222","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.1A);None;None;None","0.70A","5hi2A-4i6fA:22.7","5hesA-4i6fA:25.44"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",5,"ALA A 109;LYS A 111;ILE A 157;PHE A 212;GLY A 222","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.0A);None","0.63A","5hieA-4i6fA:21.7","5hi2A-4i6fA:27.50"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",5,"ALA A 109;LYS A 111;ILE A 157;PHE A 212;GLY A 222","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.0A);None","0.65A","5hieB-4i6fA:21.7","5hieA-4i6fA:27.96"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",5,"ALA A 109;LYS A 111;ILE A 157;PHE A 212;GLY A 222","1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.0A);None","0.63A","5hieD-4i6fA:21.8","5hieB-4i6fA:27.96"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",4,"ALA A 109;GLU A 130;CYH A 162;ASP A 223","1C7 A 401 (-3.2A);None;1C7 A 401 (-4.1A);None","0.52A","5owrA-4i6fA:23.4","5hieD-4i6fA:27.96"],["5VC3_A_DB8A601_1","WEE1-LIKE PROTEIN KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",7,"GLY A  89;ALA A 109;GLU A 130;TYR A 161;CYH A 162;PHE A 212;ASP A 223","1C7 A 401 ( 4.8A);1C7 A 401 (-3.2A);None;1C7 A 401 (-3.5A);1C7 A 401 (-4.1A);1C7 A 401 (-4.0A);None","0.81A","5vc3A-4i6fA:25.2","5owrA-4i6fA:30.46"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"LEU A  88;ALA A 109;GLU A 130;VAL A 143;PHE A 212;GLY A 222","1C7 A 401 ( 4.4A);1C7 A 401 (-3.2A);None;1C7 A 401 (-4.5A);1C7 A 401 (-4.0A);None","0.69A","5vcvA-4i6fA:24.8","5vc3A-4i6fA:24.71"],["5VCV_A_1N1A404_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","4i6f","SERINE\/THREONINE-PROTEIN KINASE PLK2","Homo sapiens",6,"LEU A  88;ALA A 109;LYS A 111;GLU A 130;VAL A 143;GLY A 222","1C7 A 401 ( 4.4A);1C7 A 401 (-3.2A);1C7 A 401 ( 4.7A);None;1C7 A 401 (-4.5A);None","0.85A","5vcvA-4i6fA:24.8","5vcvA-4i6fA:25.84"]]